PI3K p110γ overexpression in idiopathic pulmonary fibrosis lung tissue and fibroblast cells: In vitro effects of its inhibition

Laboratory Investigation

Volumn 93, Issue 5, 2013, Pages 566-576

  Conte, Enrico ^a   Gili, Elisa ^a   Fruciano, Mary ^a   Korfei, Martina ^b   Fagone, Evelina ^a   Iemmolo, Maria ^a   Lo Furno, Debora ^a   Giuffrida, Rosario ^a   Crimi, Nunzio ^a   Guenther, Andreas ^b   Vancheri, Carlo ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

Author keywords

fibroblasts; IPF; lung tissue; myofibroblasts; PI3K p110g

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CELL NUCLEUS ANTIGEN; CYCLIN D1; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE ALPHA; PHOSPHATIDYLINOSITOL 3 KINASE BETA; PHOSPHATIDYLINOSITOL 3 KINASE DELTA; PHOSPHATIDYLINOSITOL 3 KINASE GAMMA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CELL DIFFERENTIATION; CELL LINE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; EX VIVO STUDY; FEMALE; FIBROBLAST; FIBROSING ALVEOLITIS; FLOW CYTOMETRY; GENE SILENCING; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN VITRO STUDY; LUNG ALVEOLUS CELL; LUNG HOMOGENATE; LUNG PARENCHYMA; MALE; MOLECULAR PATHOLOGY; MYOFIBROBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; CELL GROWTH PROCESSES; CELLS, CULTURED; CLASS I PHOSPHATIDYLINOSITOL 3-KINASES; COLLAGEN; CYCLIN D1; FEMALE; FIBROBLASTS; GENE SILENCING; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; IMMUNOHISTOCHEMISTRY; LUNG; MALE; MIDDLE AGED; MYOFIBROBLASTS; PROLIFERATING CELL NUCLEAR ANTIGEN; PROTEIN ISOFORMS; PROTEIN KINASE INHIBITORS; RNA, SMALL INTERFERING; UP-REGULATION;

EID: 84877261137     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2013.6     Document Type: Article

References (34)

1. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002;165:277-304.
2. Conte E, Fruciano M, Fagone E, et al. Inhibition of PI3K prevents the proliferation and differentiation of human lung fibroblasts into myofibroblasts: the role of class I P110 isoforms. PLoS One 2011;6: e24663.
3. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002; 296:1655-1657.
4. Carracedo A, Pandolfi PP. The PTEN-PI3K pathway: of feedbacks and cross-talks. Oncogene 2008;27:5527-5541.
5. Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, et al. The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol 2010;11:329-341.
6. Marwick JA, Chung KF, Adcock IM. Phosphatidylinositol 3-kinase isoforms as targets in respiratory disease. Ther Adv Respir Dis 2010; 4:19-34.
7. Moir LM, Trian T, Ge Q, et al. Phosphatidylinositol 3-kinase isoformspecific effects in airway mesenchymal cell function. J Pharmacol Exp Ther 2011;337:557-566.
8. To Y, Ito K, Kizawa Y, et al. Targeting phosphoinositide-3-kinase-delta with theophylline reverses corticosteroid insensitivity in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010;182: 897-904.
9. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183:788-824.
10. Jordana M, Schulman J, McSharry C, et al. Heterogeneous proliferative characteristics of human adult lung fibroblast lines and clonally derived fibroblasts from control and fibrotic tissue. Am Rev Respir Dis 1988;137:579-584.
11. Fagone E, Conte E, Gili E, et al. Resveratrol inhibits transforming growth factor-beta-induced proliferation and differentiation of ex vivo human lung fibroblasts into myofibroblasts through ERK/Akt inhibition and PTEN restoration. Exp Lung Res 2011;37:162-174.
12. Korfei M, Schmitt S, Ruppert C, et al. Comparative proteomic analysis of lung tissue from patients with idiopathic pulmonary fibrosis (IPF) and lung transplant donor lungs. J Proteome Res 2011;10:2185-2205.
13. Hagood JS, Prabhakaran P, Kumbla P, et al. Loss of fibroblast Thy-1 expression correlates with lung fibrogenesis. Am J Pathol 2005;167: 365-379.
14. Lepparanta O, Pulkkinen V, Koli K, et al. Transcription factor GATA-6 is expressed in quiescent myofibroblasts in idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 2010;42:626-632.
15. Phan SH. The myofibroblast in pulmonary fibrosis. Chest 2002;122(6 Suppl):286S-289SS.
16. Chilosi M, Zamo A, Doglioni C, et al. Migratory marker expression in fibroblast foci of idiopathic pulmonary fibrosis. Respir Res 2006; 7:95.
17. El-Zammar O, Rosenbaum P, Katzenstein AL. Proliferative activity in fibrosing lung diseases: a comparative study of Ki-67 immunoreactivity in diffuse alveolar damage, bronchiolitis obliteransorganizing pneumonia, and usual interstitial pneumonia. Hum Pathol 2009;40:1182-1188.
18. Katzenstein AL, Myers JL. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Respir Crit Care Med 1998;157(4 Pt 1):1301-1315.
19. Kuhn C, McDonald JA. The roles of the myofibroblast in idiopathic pulmonary fibrosis. Ultrastructural and immunohistochemical features of sites of active extracellular matrix synthesis. Am J Pathol 1991;138: 1257-1265.
20. Li Y, Jiang D, Liang J, et al. Severe lung fibrosis requires an invasive fibroblast phenotype regulated by hyaluronan and CD44. J Exp Med 2011;208:1459-1471.
21. Flaherty KR, Toews GB, Lynch III JP, et al. Steroids in idiopathic pulmonary fibrosis: a prospective assessment of adverse reactions, response to therapy, and survival. Am J Med 2001;110:278-282.
22. King Jr TE, Schwarz MI, Brown K, et al. Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality. Am J Respir Crit Care Med 2001;164:1025-1032.
23. Xia H, Khalil W, Kahm J, et al. Pathologic caveolin-1 regulation of PTEN in idiopathic pulmonary fibrosis. Am J Pathol 2010;176: 2626-2637.
24. Clarke JH, Letcher AJ, D'santos CS, et al. Inositol lipids are regulated during cell cycle progression in the nuclei of murine erythroleukaemia cells. Biochem J 2001;357(Pt 3):905-910.
25. Divecha N, Clarke JH, Roefs M, et al. Nuclear inositides: inconsistent consistencies. Cell Mol Life Sci 2000;57:379-393.
26. Metjian A, Roll RL, Ma AD, et al. Agonists cause nuclear translocation of phosphatidylinositol 3-kinase gamma. A Gbetagamma-dependent pathway that requires the p110gamma amino terminus. J Biol Chem 1999;274:27943-27947.
27. Bacqueville D, Deleris P, Mendre C, et al. Characterization of a G protein-activated phosphoinositide 3-kinase in vascular smooth muscle cell nuclei. J Biol Chem 2001;276:22170-22176.
28. Smith GC, Ong WK, Rewcastle GW, et al. Effects of acutely inhibiting PI3K isoforms and mTOR on regulation of glucose metabolism in vivo. Biochem J 2012;442:161-169.
29. Vancheri C, Failla M, Crimi N, et al. Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology. Eur Respir J 2010; 35:496-504.
30. Fonar Y, Frank D. FAK and WNT signaling: the meeting of two pathways in cancer and development. Anticancer Agents Med Chem 2011;11:600-606.
31. Dituri F, Mazzocca A, Lupo L, et al. PI3K class IB controls the cell cycle checkpoint promoting cell proliferation in hepatocellular carcinoma. Int J Cancer 2012;130:2505-2513.
32. Edling CE, Selvaggi F, Buus R, et al. Key role of phosphoinositide 3-kinase class IB in pancreatic cancer. Clin Cancer Res 2010;16:4928-4937.
33. Guerreiro AS, Fattet S, Kulesza DW, et al. A sensitized RNA interference screen identifies a novel role for the PI3K p110gamma isoform in medulloblastoma cell proliferation and chemoresistance. Mol Cancer Res 2011;9:925-935.
34. Wei X, Han J, Chen ZZ, et al. A phosphoinositide 3-kinasegamma inhibitor, AS605240 prevents bleomycin-induced pulmonary fibrosis in rats. Biochem Biophys Res Commun 2010;397:311-317.